Zydus Cadila Healthcare Ltd – Product Pipeline Review

Global Markets Direct’s, ‘Zydus Cadila Healthcare Ltd – Product Pipeline Review – 2016’, provides an overview of the Zydus Cadila Healthcare Ltd’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Zydus Cadila Healthcare Ltd, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Zydus Cadila Healthcare Ltd

The report provides overview of Zydus Cadila Healthcare Ltd including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Zydus Cadila Healthcare Ltd’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Zydus Cadila Healthcare Ltd’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Zydus Cadila Healthcare Ltd’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Zydus Cadila Healthcare Ltd

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Zydus Cadila Healthcare Ltd’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Zydus Cadila Healthcare Ltd Snapshot 9

Zydus Cadila Healthcare Ltd Overview 9

Key Facts 9

Zydus Cadila Healthcare Ltd - Research and Development Overview 10

Key Therapeutic Areas 10

Zydus Cadila Healthcare Ltd - Pipeline Review 15

Pipeline Products by Stage of Development 15

Pipeline Products - Monotherapy 16

Pipeline Products - Combination Treatment Modalities 17

Pipeline Products - Partnered Products 18

Partnered Products/Combination Treatment Modalities 19

Zydus Cadila Healthcare Ltd - Pipeline Products Glance 20

Zydus Cadila Healthcare Ltd - Late Stage Pipeline Products 20

Pre-Registration Products/Combination Treatment Modalities 20

Phase III Products/Combination Treatment Modalities 21

Zydus Cadila Healthcare Ltd - Clinical Stage Pipeline Products 22

Phase II Products/Combination Treatment Modalities 22

Phase I Products/Combination Treatment Modalities 23

Zydus Cadila Healthcare Ltd - Early Stage Pipeline Products 24

Preclinical Products/Combination Treatment Modalities 24

Discovery Products/Combination Treatment Modalities 25

Zydus Cadila Healthcare Ltd - Unknown Stage Pipeline Products 26

Unknown Products/Combination Treatment Modalities 26

Zydus Cadila Healthcare Ltd - Drug Profiles 27

(diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + tetanus) (pentavalent) vaccine - Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

(diphtheria + Haemophilus influenzae [serotype B] + pertussis (whole-cell) + tetanus) vaccine - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

(diphtheria + pertussis (whole-cell) + tetanus) vaccine - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

(diphtheria + tetanus) vaccine - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

(measles + mumps + rubella + varicella) vaccine - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

(measles + mumps + rubella) vaccine - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

bevacizumab biosimilar - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

Biosimilar 1 for Nephrology, Acute Myocardial Infarction and Oncology - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

Biosimilar 2 for Diabetes, Infertility and Rheumatoid Arthritis - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

Biosimilar 3 for Rheumatoid Arthritis, Acute Myocardial Infarction, Oncology and Inflammation - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

Biosimilar 4 for Acute Myocardial Infarction, Infertility, Oncology and Thrombosis - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

Biosimilar 5 for Infertility and Oncology - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

Biosimilar 6 for Infertility, Oncology and Immunology - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

Biosimilar 7 for Infertility, Immunology and Oncology - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

Crimean-Congo hemorrhagic fever vaccine - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

Ebola vaccine - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

Haemophilus influenzae B vaccine - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

hepatitis A vaccine - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

hepatitis B vaccine - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

hepatitis E vaccine - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

human papillomavirus vaccine - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

influenza [strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (tetravalent, split virion) vaccine - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, split virion) vaccine - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, virus like particle) vaccine - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

interferon beta-1b - Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

Japanese encephalitis vaccine - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

MAb-1 - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

MAb-2 - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

MAb-3 - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

MAb-4 - Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

malaria vaccine - Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

measles vaccine - Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

PEG-EPO - Drug Profile 59

Product Description 59

Mechanism Of Action 59

R&D Progress 59

Rabimabs - Drug Profile 60

Product Description 60

Mechanism Of Action 60

R&D Progress 60

rituximab biosimilar - Drug Profile 61

Product Description 61

Mechanism Of Action 61

R&D Progress 61

saroglitazar - Drug Profile 62

Product Description 62

Mechanism Of Action 62

R&D Progress 62

tetanus vaccine - Drug Profile 65

Product Description 65

Mechanism Of Action 65

R&D Progress 65

typhoid vaccine - Drug Profile 66

Product Description 66

Mechanism Of Action 66

R&D Progress 66

ZYAN-1 - Drug Profile 67

Product Description 67

Mechanism Of Action 67

R&D Progress 67

ZYDPLA-1 - Drug Profile 68

Product Description 68

Mechanism Of Action 68

R&D Progress 68

ZYH-7 - Drug Profile 69

Product Description 69

Mechanism Of Action 69

R&D Progress 69

ZYTP-1 - Drug Profile 70

Product Description 70

Mechanism Of Action 70

R&D Progress 70

Zydus Cadila Healthcare Ltd - Pipeline Analysis 71

Zydus Cadila Healthcare Ltd - Pipeline Products by Target 71

Zydus Cadila Healthcare Ltd - Pipeline Products by Route of Administration 73

Zydus Cadila Healthcare Ltd - Pipeline Products by Molecule Type 74

Zydus Cadila Healthcare Ltd - Pipeline Products by Mechanism of Action 75

Zydus Cadila Healthcare Ltd - Dormant Projects 77

Zydus Cadila Healthcare Ltd - Company Statement 78

Zydus Cadila Healthcare Ltd - Locations And Subsidiaries 80

Head Office 80

Other Locations & Subsidiaries 80

Appendix 83

Methodology 83

Coverage 83

Secondary Research 83

Primary Research 83

Expert Panel Validation 83

Contact Us 83

Disclaimer 84

List of Tables

List of Tables

Zydus Cadila Healthcare Ltd, Key Facts 9

Zydus Cadila Healthcare Ltd – Pipeline by Indication, 2016 11

Zydus Cadila Healthcare Ltd – Pipeline by Stage of Development, 2016 15

Zydus Cadila Healthcare Ltd – Monotherapy Products in Pipeline, 2016 16

Zydus Cadila Healthcare Ltd – Combination Treatment Modalities in Pipeline, 2016 17

Zydus Cadila Healthcare Ltd – Partnered Products in Pipeline, 2016 18

Zydus Cadila Healthcare Ltd – Partnered Products/ Combination Treatment Modalities, 2016 19

Zydus Cadila Healthcare Ltd – Pre-Registration, 2016 20

Zydus Cadila Healthcare Ltd – Phase III, 2016 21

Zydus Cadila Healthcare Ltd – Phase II, 2016 22

Zydus Cadila Healthcare Ltd – Phase I, 2016 23

Zydus Cadila Healthcare Ltd – Preclinical, 2016 24

Zydus Cadila Healthcare Ltd – Discovery, 2016 25

Zydus Cadila Healthcare Ltd – Unknown, 2016 26

Zydus Cadila Healthcare Ltd – Pipeline by Target, 2016 72

Zydus Cadila Healthcare Ltd – Pipeline by Route of Administration, 2016 73

Zydus Cadila Healthcare Ltd – Pipeline by Molecule Type, 2016 74

Zydus Cadila Healthcare Ltd – Pipeline Products by Mechanism of Action, 2016 76

Zydus Cadila Healthcare Ltd – Dormant Developmental Projects,2016 77

Zydus Cadila Healthcare Ltd, Other Locations 80

Zydus Cadila Healthcare Ltd, Subsidiaries 81

List of Figures

List of Figures

Zydus Cadila Healthcare Ltd – Pipeline by Top 10 Indication, 2016 11

Zydus Cadila Healthcare Ltd – Pipeline by Stage of Development, 2016 15

Zydus Cadila Healthcare Ltd – Monotherapy Products in Pipeline, 2016 16

Zydus Cadila Healthcare Ltd – Combination Treatment Modalities in Pipeline, 2016 17

Zydus Cadila Healthcare Ltd – Partnered Products in Pipeline, 2016 18

Zydus Cadila Healthcare Ltd – Pipeline by Top 10 Target, 2016 71

Zydus Cadila Healthcare Ltd – Pipeline by Route of Administration, 2016 73

Zydus Cadila Healthcare Ltd – Pipeline by Molecule Type, 2016 74

Zydus Cadila Healthcare Ltd – Pipeline Products by Top 10 Mechanism of Action, 2016 75

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2960

Saved reports